---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-25-000886"
form_type: "8-K"
ticker: "LCTC"
cik: "0001493137"
company_name: "Lifeloc Technologies, Inc"
filed_at: "2025-05-16T23:59:59+00:00"
generated_at: "2026-05-21T03:07:19.376272+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lifeloc Q1 revenue up 6% to $2.28M, net loss $(293k) from $(284k) YoY

## Summary
- Q1 net revenue $2.277M (+6% YoY); net loss $(293k) or $(0.11) per diluted share.
- Gross margin improved to 39.9% from 38.8%; R&D spending >20% of revenue for SpinDx development.
- SpinDx beta testing with Anschutz Medical Center imminent; commercial launch targeted for 2026.
- Applied for OTCID listing on OTC Markets, effective July 1, 2025, replacing OTC Pink.

## SEC filing metadata
- accession: 0001079973-25-000886
- form_type: 8-K
- ticker: LCTC
- cik: 0001493137
- company_name: Lifeloc Technologies, Inc
- filed_at: 2025-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1493137/000107997325000886/0001079973-25-000886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1493137/000107997325000886/lctc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-25-000886
- JSON: https://secwatch.observer/filing/0001079973-25-000886.json
- Plain text: https://secwatch.observer/filing/0001079973-25-000886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.